Phaseline

Companies › Nykode Therapeutics ASA

Nykode Therapeutics ASA: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Jan 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
VB10.16
Therapeutic DNA vaccine targeting HPV16
–Phase 1HPV Positive Oropharyngeal Squamous Cell CarcinomaJan 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06016920VB10.16Phase 1HPV Positive Oropharyngeal Squamous Cell CarcinomaOncologyJan 2029

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.